Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Pfizer's Bold Move in Obesity Market, FDA's Autism Initiative, and Psychedelics Revival Shape Pharma Landscape

Pfizer has made a significant leap into the competitive obesity treatment market with its acquisition of Metsera, while the FDA explores new uses for existing drugs in autism treatment. Meanwhile, the psychedelics sector is heating up with potential for further M&A activity. These developments, along with policy changes and rare disease approvals, are reshaping the pharmaceutical industry landscape.

NoahAI News9/25/2025

Cardiosense Appoints New CEO to Drive Growth of Wearable Heart Monitor

Cardiosense, a healthcare technology company specializing in cardiac monitoring, has announced the appointment of Eric Meizlish as its new Chief Executive Officer. This strategic move comes as the company looks to capitalize on the recent FDA clearance of its CardioTag wearable heart monitor and expand its artificial intelligence capabilities.

NoahAI News9/25/2025

Physician Practice Acquisitions on the Rise: Implications for Healthcare Costs and Quality

The healthcare landscape is undergoing a significant transformation as physician practices increasingly become targets for acquisition by larger entities. A recent review by the Government Accountability Office (GAO) sheds light on this growing trend and its potential impacts on healthcare costs and quality.

NoahAI News9/25/2025

Hengrui Pharma's $1.1B Deal with Glenmark Marks Latest Move in ADC Market

Jiangsu Hengrui Pharmaceuticals has inked a potential $1.1 billion licensing agreement with Glenmark Pharmaceuticals, signaling another major development in the increasingly competitive antibody-drug conjugate (ADC) market. The deal centers on trastuzumab rezetecan, Hengrui's HER2-targeted ADC positioned as a rival to AstraZeneca and Daiichi Sankyo's blockbuster Enhertu.

NoahAI News9/25/2025

Harmony's Fragile X Trial Disappoints as High Placebo Response Derails Results

Harmony Biosciences' ambitious $60 million gamble on a previously unsuccessful Fragile X syndrome treatment has encountered a significant setback. The company reported that its registrational trial for ZYN002, a synthetic cannabidiol, failed to meet its primary endpoint, dealing a blow to hopes for a new therapeutic option for this rare genetic disorder.

NoahAI News9/25/2025

Privia Health Acquires Evolent Care Partners for $100M, Expanding Value-Based Care Footprint

Privia Health, a leading physician enablement company, has announced the acquisition of Evolent Health's accountable care organization (ACO) business, Evolent Care Partners, for $100 million in cash. The deal, which is expected to close in the fourth quarter, marks a significant expansion of Privia's value-based care network and reinforces its position in the rapidly evolving healthcare landscape.

NoahAI News9/25/2025

FDA Requests Additional Manufacturing Information for High-Dose Spinraza, Delaying Approval

Biogen faces an unexpected setback in its pursuit of approval for a high-dose regimen of Spinraza (nusinersen) in spinal muscular atrophy (SMA) patients. The U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to the company, requesting updates to technical information in the chemistry, manufacturing, and controls portion of the application.

NoahAI News9/25/2025

Pharma's Next-Gen Antibodies: Multi-Targeting Approach Gains Traction in Oncology and Autoimmune Diseases

The pharmaceutical industry is witnessing a surge in the development and testing of multifunctional antibodies, with a particular focus on bispecific and higher-order multispecific antibodies (msAbs). These advanced therapeutics, capable of targeting two or more sites simultaneously, are attracting significant investment and showing promise in both oncology and autoimmune diseases.

NoahAI News9/25/2025

Thyme Care Secures $97M Series D Funding, Expands Cancer Care Navigation Services

Thyme Care, a value-based cancer care navigation company, has raised $97 million in a Series D funding round, propelling its valuation to over $1 billion. The investment, backed by major strategic players across the healthcare spectrum, aims to accelerate the company's growth and enhance its oncology support services.

NoahAI News9/25/2025

Cyclerion Therapeutics Pivots to Neuropsychiatry with MIT-Licensed Technology

Cyclerion Therapeutics, a Cambridge, Massachusetts-based biotech company, has announced a significant strategic shift, repositioning itself as a neuropsychiatric-focused entity. This latest pivot marks a dramatic departure from the company's previous endeavors and introduces a novel approach to treating mental health disorders.

NoahAI News9/25/2025

Merck Licenses AI-Driven Vaccine Candidate from Evaxion in $592M Deal

Merck & Co. has exercised its option to license a preclinical vaccine candidate from Danish biotech Evaxion Biotech, marking a significant development in the application of artificial intelligence to vaccine discovery. The deal, potentially worth up to $592 million, underscores the growing interest in AI-driven approaches to addressing global health challenges.

NoahAI News9/25/2025

Acadia's PWS Candidate Failure Leaves Soleno Unchallenged in Hyperphagia Market

Acadia Pharmaceuticals' phase 3 trial for its intranasal carbetocin treatment for hyperphagia in Prader-Willi Syndrome (PWS) has failed to meet its primary endpoint, leading the company to discontinue further development of the candidate. This setback leaves Soleno Therapeutics as the sole player in the market for hyperphagia treatments associated with PWS.

NoahAI News9/25/2025

«1...64 65 66 67 »